Thyroid-Stimulating Immunoglobulin Assay for Graves’ Disease Detection
Graves’ disease (GD) is caused by circulating autoantibodies that stimulate the TSH receptor (TSHR), leading to unregulated production and secretion of thyroid hormones. Measurement of TSHR antibodies (TRAb) in patient serum is a sensitive tool to assess GD. In addition to diagnosis, there are several other clinical implications where TRAb measurement is valuable. Functionally, TRAb can be divided into two main categories – thyroid-stimulating antibodies (TSAb, TSI) and thyroid-blocking antibodies (TBAb, TBI) – that can (co)exist in patients with GD.
In this webinar, we will discuss:
- Clinical and pathophysiological aspects of GD, including Graves’ orbitopathy
- TRAb nomenclature
- Different types of TRAb bindings and functional assays
- Clinical application of the TSI assay
Key learning objectives
- Explain the clinical and pathophysiological aspects of Graves’ disease, including Graves’ orbitopathy
- Determine the different types of TRAb bindings and functional assays
- Discuss the clinical application of the TSI assay
Who should attend
- Clinicians
- Laboratorians
- Specialists
- Government decision makers
- Healthcare professionals
Accreditation statement
SelectScience is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program. Attendees of this one-hour webinar are also entitled to 1.0 ACCENT Continuing Education Credits from the ADLM. This activity was planned in accordance with ACCENT® Standards and Policies. Verification of Participation certificates are provided to registered participants based on completion of the activity, in its entirety, and the activity evaluation. For questions regarding continuing education, please email education@myadlm.org.